Statement of Robert J. Lieberman Assistant Inspector General Department of Defense Before the Senate Armed Services Committee on Defense Anthrax Vaccine Contracting
Abstract
In summary, we determined that applicable laws and regulations allowed the Department to provide extraordinary relief to BioPort Corporation during late FY 1999, but significant risks continued. Because there appears to be no alternative U.S. domestic source, at least in the near term, the DoD anthrax vaccination policy is viable only if BioPort can bring its production facility up to Food and Drug Administration standards this year. Beyond the current issues concerning AVA, however, we believe the DoD and Congress need to continue working toward a comprehensive, long term defensive strategy against the spectrum of potential chemical and biological warfare threats. Our work in DoD chemical and biological defense programs, as outlined in the attached list of reports and testimony, has indicated a wide range of unresolved issues and difficult challenges in this broad area, whose importance to national security will surely continue to grow in the coming years.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 12, 2000
- Accession Number
- ADA379267
Entities
Organizations
- Office of the Inspector General, U.S. Department of Defense